Sichenzia Ross Ference LLP Represents Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE) in Offering of $1.2 Million American Depositary Shares
Press Release – New York, NY – May 23, 2019 – Sichenzia Ross Ference LLP announced today that it represented Genetic Technologies Limited (ASX: GTG; Nasdaq: GENE), a diversified molecular diagnostics company, in a registered direct offering of American Depositary Shares (“ADSs”) and warrants to purchase ADSs. The Company received gross proceeds of approximately $1,200,000.
The Sichenzia Ross Ference LLP team was led by Partners Darrin Ocasio and Avital Perlman, Of Counsel Jeff Cahlon and Associate Grant Levine.
- Sichenzia Ross Ference LLP Announces Over 80 Capital Markets Transactions Valued Over $2 Billion at the Closing of 2021 - January 13, 2022
- Sichenzia Ross Ference LLP Adds Two Key Additions to its Corporate and Securities Law Team - January 11, 2022
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $9.8 Million Underwritten Offering of BiondVax Pharmaceuticals Ltd. - December 30, 2021